Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity

Neurobiology of Aging

Volumn 31, Issue 2, 2010, Pages 203-214

  Taddei, K ^a,b   Laws, S M ^a,b,c   Verdile, G ^a,b   Munns, S ^b   D'Costa, K ^b   Harvey, A R ^b   Martins, I J ^a   Hill, F ^b   Levy, E ^d   Shaw, J E ^e   Martins, R N ^a,b  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Beta amyloid; Drug development; Neutralization; Peptides; Phage display

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMYLOID BETA PROTEIN INHIBITOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CLIOQUINOL; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; PROTEIN INHIBITOR; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL ASSAY; CHELATION; CONTROLLED STUDY; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; INHIBITION KINETICS; NEUROBLASTOMA CELL; NEUROTOXICITY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING;

AMYLOID BETA-PROTEIN; ANIMALS; BACTERIOPHAGES; CELL LINE, TUMOR; CELL SURVIVAL; CLIOQUINOL; ESCHERICHIA COLI; GENETIC TECHNIQUES; HUMANS; HYDRO-LYASES; HYDROGEN PEROXIDE; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; RATS; SEQUENCE ANALYSIS, DNA; SUPEROXIDE DISMUTASE;

EID: 71349083518     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.03.023     Document Type: Article

References (59)

1. Abe K., and Saito H. Both oxidative stress-dependent and independent effects of amyloid beta protein are detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Brain Res. 830 (1999) 146-154
2. Access Economics Pty Ltd., March 2003. The Dementia Epidemic: Economic Impact and Positive Solutions for Australia. Prepared for Alzheimer's Australia.
3. Atwood C.S., Moir R.D., Huang X., Scarpa R.C., Baccara M., Romano D.M., Hartshorn M.A., Tanzi R.E., and Bush A.I. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273 (1998) 12817-12826
4. Atwood C.S., Huang X., Khatri A., Scarpa R.C., Kim Y.S., Moir R.D., Tanzi R.E., Roher A.E., and Bush A.I. Copper catalyzed oxidation of Alzheimer Aβ. Cell. Mol. Biol. 46 (2000) 777-783
5. Atwood C.S., Perry G., Zeng H., Kato Y., Jones W.D., Ling K., Huang X., Moir R.D., Wong D., Sayre L.M., Smith M.A., Chen S.G., and Bush A.I. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-β. Biochemistry 43 (2004) 560-568
6. Barnham K.J., Ciccotosto G.D., Tickler A.K., Ali F.E., Smith D.G., Williamson N.A., Lam Y.H., Carrington D., Tew D., Kocak G., Volitakis I., Separovic F., Barrow C.J., Wade J.D., Masters C.l., Cherny R.A., Curtain C.C., Bush A.I., and Cappai R. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278 (2003) 42959-42965
7. Barnham K.J., Haeffner F., Ciccotosto G.D., Curtain C.C., Tew D., Mavros C., Beyreuther K., Carrington D., Masters C.L., Cherny R.A., Cappai R., and Bush A.I. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 18 (2004) 1427-1429
8. Behl C., Davis J.B., Lesley R., and Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77 (1994) 1-20
9. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 26 (2003) 207-214 Review
10. Bush A.I., Lynch T., Cherny R.C., Atwood C.S., Goldstein L.E., Moir R.D., Li Q.-X., Cabelli D.E., Multhaup G., Masters C.L., Tanzi R.E., and Huang X. Alzheimer Aβ functions as superoxide antioxidant in vitro and in vivo. Soc. Neurosci. Abstr. 25 (1999) 14
11. Butterfield D.A., and Bush A.I. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol. Aging 25 (2004) 563-568 (review)
12. Butterfield D.A., Drake J., Pocernich C., and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7 (2001) 548-554
13. Chan C.-W., Dharmarajan A., Atwood C.S., Huang X., Tanzi R.E., Bush A.I., and Martins R.N. Anti-apoptotic action of Alzheimer Aβ. Alzheimer's Rep. 2 (1999) 113-119
14. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., and Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
15. Ciccotosto G.D., Tew D., Curtain C.C., Smith D., Carrington D., Masters C.L., Bush A.I., Cherny R.A., Cappai R., and Barnham K.J. Enhanced toxicity and cellular binding of a modified amyloid β peptide with a methionine to valine substitution. J. Biol. Chem. 279 (2004) 42528-42534
16. Citron M. Secretases as targets for the treatment of Alzheimer's disease. Mol. Med. Today 6 (2000) 392-397 (review)
17. Cuajungco M.P., Goldstein L.E., Nunomura A., Smith M.A., Lim J.T., Atwood C.S., Huang X., Farrag Y.W., Perry G., and Bush A.I. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J. Biol. Chem. 275 (2000) 19439-19442
18. Datamonitor Report, 2002. Entitled "Drugs of Tomorrow: Alzheimer's Disease". Reference Code: DMHC1788. Publication Date: 23/07/2002.
19. Deshpande A., Mina E., Glabe C.G., and Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26 (2006) 6011-6018
20. Fonte J., Miklossy J., Atwood C., and Martins R.N. The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-β levels: resolublization of amyloid-β with transition metal ion chelators. J. Alzheimers Dis. 3 (2001) 209-219
21. Geerts H. NC-531 (Neurochem). Curr. Opin. Invest. Drugs 5 (2004) 95-100
22. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984) 885-890
23. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., and Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131 (1995) 193-200
24. Head E., Garzon-Rodriguez W., Johnson J.K., Lott I.T., Cotman C.W., and Glabe C. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol. Dis. 8 (2001) 792-806
25. Huang X., Atwood C.S., Moir R.D., Hartshorn M.A., Vonsattel J.-P., Tanzi R.E., and Bush A.I. Zinc-induced Alzheimer's Aβ 1-40 aggregation is mediated by conformational factors. J. Biol. Chem. 272 (1997) 26464-26470
26. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E., and Bush A.I. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38 (1999) 4595-4603
27. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., Scarpa R.C., Saunders A.J., Lim J., Moir R.D., Glabe C., Bowden E.F., Masters C.L., Fairlie D.P., Tanzi R.E., and Bush A.I. Cu(II) potentiation of Alzheimer abeta neurotoxicity Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 24 (1999) 37111-37116
28. in t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., and Stricker B.H. Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345 (2001) 1515-1521
29. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.-H., Multhaup G., Beyreuther K., and Muller-Hill B. The precursor of Alzheimer's disease amyloid βA4 protein resembles a cell surface receptor. Nature 325 (1987) 733-736
30. 2+ in a mononuclear metal ion binding site. J. Am. Chem. Soc. 126 (2004) 13534-13538
31. Kawahara M., and Kuroda Y. Molecular mechanism of neurodegeneration induced by Alzheimer's β-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res. Bull. 53 (2000) 389-397
32. Kontush A. Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic. Biol. Med. 31 (2001) 1120-1131 Review
33. Kontush A., Berndt C., Weber W., Akopyan V., Arlt S., Schippling S., and Beisiegel U. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 30 (2001) 119-128
34. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., and Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158 (1998) 47-52
35. Mantyh P.W., Ghilardi J.R., Rogers S., DeMaster E., Allen C.J., Stimson E.R., and Maggio J.E. Aluminium, iron and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J. Neurochem. 61 (1993) 1171-1174
36. Mark R.J., Pang Z., Geddes J.W., Uchida K., and Mattson M.P. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17 (1997) 1046-1054
37. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 4245-4249
38. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
39. Müller W.E., Koch S., Eckert A., Hartmann H., and Scheuer K. β-Amyloid peptide decreases membrane fluidity. Brain Res. 674 (1995) 133-136
40. Nishi T., Budde R.J., McMurraym J.S., Obeyesekerem N.U., Safdarm N., Levinm V.A., and Sayam H. Tight-binding inhibitory sequences against pp60(c-src) identified using a random 15-amino-acid peptide library. FEBS Lett. 399 (1996) 237-240
41. Nishino S., and Nishida Y. Oxygenation of amyloid beta-peptide (1-40) by copper(II) complex and hydrogen peroxide system. Inorg. Chem. Commun. 4 (2001) 86-89
42. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., and Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19 (1999) 1959-1964
43. Opazo C., Huang X., Cherny R.A., Moir R.D., Roher A.E., White A.R., Cappai R., Masters C.L., Tanzi R.E., Inestrosa N.C., and Bush A.I. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277 (2002) 40302-40308
44. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6 (2003) 345-351 (review)
45. Puglielli L., Friedlich A.L., Setchell K.D., Nagano S., Opazo C., Cherny R.A., Barnham K.J., Wade J.D., Melov S., Kovacs D.M., and Bush A.I. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J. Clin. Invest. 115 (2005) 2556-2563
46. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.-X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., and Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
47. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T., Mar L., Sorbi S., Nacmias B., Piacentini S., Amaducci L., Chumakov I., Cohen D., Lannfelt L., Fraser P.E., Rommens J.M., and St George-Hyslop P.H. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
48. Sayre L.M., Zagorski M.G., Surewicz W.K., Krafft G.A., and Perry G. Mechanisms of neurotoxicity associated with amyloid β deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. Chem. Res. Toxicol. 10 (1997) 518-526
49. Schenk D. Hopes remain for an Alzheimer's vaccine. Nature 431 (2004) 398 (review)
50. Skovronsky D.M., Lee V.M.Y., and Trojanowski J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 1 (2006) 151-170 (review)
51. Scott J.K., and Smith G.P. Searching for peptide ligands with an epitope library. Science 249 (1990) 386-390
52. Smith M.A., Harris P.L.R., Sayre L.M., and Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 9866-9868
53. Smith G.P., and Scott J.K. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 217 (1993) 228-257
54. Syme C.D., Nadal R.C., Rigby S.E., and Viles J.H. Copper binding to the amyloid-β (Aβ) peptide associated with Alzheimer's disease. J. Biol. Chem. 279 (2004) 18169-18177
55. Tariot P.N., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
56. Verdile G., Fuller S., Atwood C.S., Laws S.M., Gandy S.E., and Martins R.N. The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. Pharmacol. Res. 50 (2004) 397-409 (review)
57. Veurink G., Fuller S.J., Atwood C.S., and Martins R.N. Genetics, lifestyle and the roles of amyloid-β and oxidative stress in Alzheimer's disease. Ann. Hum. Biol. 30 (2003) 639-667 (review)
58. Walsh D.M., and Selkoe D.J. Aβ oligomers-a decade of discovery. J. Neurochem. 101 (2007) 1172-1184
59. Yatin S.M., Varadarajan S., Link C.D., and Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol. Aging 20 (1999) 325-330